Toxocariasis Might be an Important Cause of Atopic Myelitis in Korea

Atopic myelitis is defined as myelitis with atopic diathesis but the cause is still unknown. Toxocariasis is one of the common causes of hyperIgEaemia that may lead to neurologic manifestations. The purpose of this study was to evaluate the sero-prevalence of Toxocara specific IgG Ab among the atopic myelitis patients. We evaluated the medical records of 37 patients with atopic myelitis whose conditions were diagnosed between March 2001 and August 2007. Among them, the 33 sera were analyzed for specific serum IgG Ab to Toxocara excretory-secretory antigens (TES). All of 37 patients had hyperIgEaemia. Specific IgE to D. pteronyssinus and D. farinae was detected in 22 (64.7%) and 34 (100%) patients, respectively, of the 34 patients. Thirty-one of 33 patients (93.9%) were found to be positive by TES IgG enzyme-linked immunosorbent assay (ELISA). Based on the image findings of eosinophilic infiltrations in the lung and liver, 8 patients had positive results. These results inferred that the prevalence of toxocariasis was high in patients with atopic myelitis. Our results suggest that toxocariasis might be an important cause of atopic myelitis and Toxocara ELISA is essential for evaluating the causes of atopic myelitis.

Key Words: Myelitis; Atopy; Toxocariasis

INTRODUCTION

Atopic myelitis (myelitis with atopic diathesis, AM) is a disease entity that is characterized by the association between allergic and central nervous system (CNS) disease, and it is usually defined as myelitis of an unknown cause with either 1) hyperIgEaemia and mite antigen-specific IgE positivity or 2) coexistent atopic disease (1). AM was first described by Kira et al. in 1997, and they reported 4 cervical myelitis patients with associated hyperIgEaemia and atopic dermatitis (2). AM has been reported in nearly 100 patients particularly in Japanese patients, and it is characterized by distinct features such as 1) stepwise progression and fluctuation of the clinical course, 2) paresthesia and/or dyesthesia as the predominant symptoms, 3) the relatively infrequent occurrence of muscle weakness, 4) T2-high signal intensity lesions on magnetic resonance imaging (MRI), 5) hyperIgEaemia, 6) mite antigen-specific IgE positivity, 7) mild peripheral blood eosinophilia, and 8) eosinophilic inflammation on spinal cord biopsy (1, 3, 4). Therefore, an allergic mechanism such as cross-reactivity between environmental allergens and CNS antigens is thought to be important for this condition (5). But the pathogenesis of the disease is still unclear.

Toxocariasis is an ubiquitous parasitic infection by Toxocara canis or T. cati in man, the accidental hosts. It is caused by ingesting eggs in soil or by eating uncooked/undercooked animal liver or meat containing the infective-stage larvae (6, 7). The larvae hatch in the proximal small intestine, penetrate the mucosa, migrate into the liver and lung, and then they enter the systemic circulation till their progress is impeded (8). They eventually penetrate the capillaries and migrate aimlessly into the host tissue. The migrating larvae leave tracks of hemorrhage, necrosis and inflammatory cells and they induce immune-mediated hypersensitivity reactions that may lead to clinical manifestations with peripheral blood eosinophilia and hyperIgEaemia (8). The diagnosis is made by serologic confirmation using the enzyme-linked immunosorbent assay (ELISA) with Toxocara excretory-secretory antigens (TES-Ag) (9, 10) or the diagnosis is made, on rare occasions, by tissue biopsy (11). The seroprevalence of toxocariasis in rural Korean adults was detected to be approximately 5% (12) although the seroprevalence of toxocariasis varies depending on the other country (13).

Myelitis due to T. canis is a rare disease. It has been report-
Toxocara Myelitis

There is a need to gain insight into a link between AM and prevalence of AM. The existence of such patients prompted us to study the factors that contribute to the clinical data of the patients, including the age at onset, gender, a history of preceding atopic diseases, a history of raw food intake or eating raw fresh-water fish within 6 months of symptom development, male food intake that included raw liver, raw meat or raw freshwater fish within 6 months of symptom development, mode of onset, the clinical course, the clinical symptoms and signs, the location of lesions (MRI lesions), other organ involvements including the lung and liver (by plain chest radiography, computed tomography, or hepatic sonography), stool examinations, laboratory findings of peripheral blood eosinophil counts, serum total IgE and allergen-specific IgE levels, the eosinophilic cationic protein (ECP) levels, parasite ELISA, the Toxocara specific IgG levels, and the cell counts in cerebrospinal fluid (CSF).

The mode of onset was defined as either acute (reaching maximum intensity within 1 month) or chronic (reaching maximum intensity after 1 month). Eosinophilia was defined as more than 500 cells/µL in peripheral blood or more than 5% in CSF. The serum total IgE and two common mite antigens, Dermatophagoides pteronyssinus and Dermatophagoides farinae-specific IgE levels were measured using an ImmunoCAP-250 (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). The upper normal limits of the serum total IgE and the mite antigen-specific IgE levels are 250 U/mL and 0.34 U/mL, respectively.

Specific IgG antibodies to parasite (Paragonimus, Sparganum, Cysticercus, and Clonorchis) in the serum and the CSF were measured at the Department of Clinical and Laboratory Medicine of Yong-San Hospital, Chung-Ang University (Seoul, Korea). The serologic diagnosis of toxocariasis by TES IgE Western blot analysis of the serum was also performed to eliminate possible cross-reactions. The TES Ag were kindly supplied by Dr. Sun Huh (Department of Parasitology, College of Medicine, Hallym University, Chuncheon, Korea).

All patients had supportive therapy with systemic corticosteroid and some had additive albendazole therapy (800 mg/day for 28 days). The outcome score was determined according to a score system (0, complete resolution; 1, near complete resolution; 2, marked improvement; 3, moderate improvement; 4, minimal improvement; 5, relapse and/or aggravation). Patients with outcome score 5 were defined as non-responders and others were defined as responders.

Methodology

We retrospectively analyzed the medical records of 37 patients with AM who visited our clinic between March 2001 and August 2007. AM was defined as myelitis of unknown cause with either 1) hyperIgEaemia and mite antigen-specific IgE positivity, or 2) coexistent atopic disease such as atopic dermatitis, allergic rhinitis, bronchial asthma and food allergy as described by Ösoegawa et al. (1). The study was approved by the research ethics committee at the Samsung Medical Center, and 33 of the subjects gave a written informed consent.

Materials and Methods

Subjects

We retrospectively analyzed the medical records of 37 patients with AM who visited our clinic between March 2001 and August 2007. AM was defined as myelitis of unknown cause with either 1) hyperIgEaemia and mite antigen-specific IgE positivity, or 2) coexistent atopic disease such as atopic dermatitis, allergic rhinitis, bronchial asthma and food allergy as described by Ösoegawa et al. (1). The study was approved by the research ethics committee at the Samsung Medical Center, and 33 of the subjects gave a written informed consent.

Methods

The medical records were reviewed for information related to the clinical data of the patients, including the age at onset, gender, a history of preceding atopic diseases, a history of raw food intake that included raw liver, raw meat or raw freshwater fish within 6 months of symptom development, mode of onset, the clinical course, the clinical symptoms and signs, the location of lesions (MRI lesions), other organ involvements including the lung and liver (by plain chest radiography, computed tomography, or hepatic sonography), stool examinations, laboratory findings of peripheral blood eosinophil counts, serum total IgE and allergen-specific IgE levels, the eosinophilic cationic protein (ECP) levels, parasite ELISA, the Toxocara specific IgG levels, and the cell counts in cerebrospinal fluid (CSF).

The mode of onset was defined as either acute (reaching maximum intensity within 1 month) or chronic (reaching maximum intensity after 1 month). Eosinophilia was defined as more than 500 cells/µL in peripheral blood or more than 5% in CSF. The serum total IgE and two common mite antigens, Dermatophagoides pteronyssinus and Dermatophagoides farinae-specific IgE levels were measured using an ImmunoCAP-250 (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). The upper normal limits of the serum total IgE and the mite antigen-specific IgE levels are 250 U/mL and 0.34 U/mL, respectively.

Specific IgG antibodies to parasite (Paragonimus, Sparganum, Cysticercus, and Clonorchis) in the serum and the CSF were measured at the Department of Clinical and Laboratory Medicine of Yong-San Hospital, Chung-Ang University (Seoul, Korea). The serologic diagnosis of toxocariasis by TES IgE Western blot analysis of the serum was also performed to eliminate possible cross-reactions. The TES Ag were kindly supplied from Dr. Sun Huh (Department of Parasitology, College of Medicine, Hallym University, Chuncheon, Korea).

All patients had supportive therapy with systemic corticosteroid and some had additive albendazole therapy (800 mg/day for 28 days). The outcome score was determined according to a score system (0, complete resolution; 1, near complete resolution; 2, marked improvement; 3, moderate improvement; 4, minimal improvement; 5, relapse and/or aggravation). Patients with outcome score 5 were defined as non-responders and others were defined as responders.

Statistical analysis

The data was analyzed by SAS. The relationships among the eosinophil counts, the laboratory data and organ involvement were analyzed by Mann-Whitney U test. We performed Pearson’s correlation analysis, and Spearman’s correlation analysis for the non-parametric distributions.
RESULTS

Patient characteristics and clinical findings

The clinical data is summarized in Table 1. The male/female ratio was 36:1. The age at onset was 47 ± 13 (Mean ± SD) yr old on average, although it varied from 23 to 74 (median = 45 yr), and 20 (55.6%) of the patients were between 20 and 49 yr old. The mean follow-up period was 570 ± 337 days (Mean ± SD, range 133-1,425 days, median 433 days). Out of the 37 subjects, 36 patients (97.3%) had a history of raw food intake history and 27 patients (73.0%) had eaten raw foods within 6 months of developing symptoms. For the 33 *Toxocara* ELISA-available patients, all the patients had a history of raw food intake and 25 patients (75.8%) had a history of raw food intake within 6 month of symptom development. Five patients (13.5%) had a history of close contact with pets. Atopic diseases were present in 14 (37.8%) of the 37 patients. The most frequent atopic diseases were allergic rhinitis (57.0%), atopic dermatitis (28.6%), food allergy (7.2%), and bronchial asthma (7.2%) in that order. The remaining 23 (62.1% patients with both hyperIgEaemia and mite antigen-specific IgE were considered to have atopic diasthesis. There were no differences of the clinical data between the patients with atopic disease and the patients with atopic diathesis.

The mode of onset was acute in 9 (24.3%) and chronic in 28 (75.7%) of the 37 patients. Stepwise progression and/or fluctuation of symptoms were seen in 23 (62.2%) and monophasic features were seen in 14 (37.8%) of the 37 AM patients. The most common initial symptoms were paresthesia and/or dysesthesia (73.0%) followed by muscle weakness (24.3%). Paresthesia and/or dysesthesia (94.6%) were also the most frequently observed symptoms/signs throughout the entire clinical course and this was followed by sensory impairment (75.7%), muscle weakness (62.2%), hyperreflexia (51.4%) and gait disturbance (43.2%) although severe muscle weakness (motor power below Grade III) or pathologic reflexes were infrequent (n=6, 16.2% and n=6, 16.2%, respectively). Autonomic dysfunctions were frequently observed in 29 (78.4%) of the 37 patients with bladder (93.1%), bowel (86.2%) and sexual dysfunction (70.0%).

Table 1. Summary of clinical data from 37 patients with atopic myelitis

| Variables                              | No. of patients | %    |
|----------------------------------------|-----------------|------|
| History of allergic disease            | 14              | 37.8 |
| Allergic rhinitis                      | 8               | 21.6 |
| Atopic dermatitis                      | 4               | 10.8 |
| Food allergy                           | 1               | 2.7  |
| Bronchial asthma                       | 1               | 2.7  |
| History of raw liver/meat              |                 |      |
| Ever                                   | 36              | 97.3 |
| Within 6 month of symptom             | 27              | 73.0 |
| History of intimate animal contact     | 5               | 13.5 |
| Mode of onset                          |                 |      |
| Acute                                  | 9               | 24.3 |
| Chronic                                | 28              | 75.7 |
| Clinical course                        |                 |      |
| Monophasic                             | 14              | 37.8 |
| Stepwise progression or fluctuating    | 23              | 62.2 |
| Initial symptoms                       |                 |      |
| Paresthesia/dysesthesia                | 27              | 73.0 |
| Motor weakness                         | 9               | 24.3 |
| Cranial nerve palsy                    | 1               | 2.7  |
| Symptoms and signs                     |                 |      |
| Paresthesia/dysesthesia                | 35              | 94.6 |
| Sensory impairment                     | 28              | 75.7 |
| Hyperreflexia                          | 19              | 51.4 |
| Autonomic disturbance                  | 29              | 78.4 |
| Urination                              | 27              | 73.0 |
| Bowel habit                            | 25              | 67.2 |
| Ejaculation                            | 20              | 54.1 |
| Motor weakness                         | 23              | 62.2 |
| More than motor power grade IV         | 17              | 45.9 |
| Below motor power grade III            | 6               | 16.2 |
| Babinski’s sign                        | 6               | 16.2 |
| Gait disturbance                       | 16              | 43.2 |

Table 2. Summary of laboratory data from 37 patients with atopic myelitis

| Variables                              | No. of patients | %    |
|----------------------------------------|-----------------|------|
| CSF                                    |                 |      |
| Pleocytosis (≥ 5/μL)                    | 4/26            | 15.4 |
| Presence of eosinophils                 | 9/26            | 34.6 |
| Eosinophilia (≥ 5%)                     | 8/26            | 30.8 |
| MRI lesions                            |                 |      |
| Localized lesion                       | 32/36           | 88.9 |
| Cervical cord                          | 12/32           | 37.5 |
| Thoracic cord                          | 14/32           | 43.8 |
| Lumbar cord                            | 1/32            | 3.1  |
| Cervical and thoracic cord             | 5/32            | 15.6 |
| T2-high intensity lesion               | 31/32           | 96.9 |
| Gaddolinium enhancement                | 24/32           | 75.0 |
| Spinal cord swelling                   | 26/32           | 81.3 |
| Image findings of eosinophilic infiltrations in lung | 4/36 | 11 |
| Urination                              |                 |      |
| Chest radiography                      | 2/36            | 6.2  |
| Chest CT                               | 3/4             | 8.1  |
| Image findings of eosinophilic infiltrations in liver | 7/22 | 32 |
| Hepatic sonography                     | 4/19            | 24.3 |
| Liver CT                               | 4/6             | 11.8 |

CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; CT, computed tomography.
Laboratory findings

The laboratory findings are summarized in Table 2. The initial peripheral blood white blood cell counts were ranged from 4,640 to 18,050/μL (median: 7,445/mL) and leukocytosis (>10,000/μL) was seen in 7 patients (18.9%). The peak peripheral blood eosinophil counts were ranged from 0 to 8,484/μL (median: 511/mL). Peripheral blood eosinophilia (>500/μL) was detected in 20 (54.1%) of 37 patients and the degree of eosinophilia was median 915/μL in these 20 patients. Of the 31 *Toxocara* sero-positive patients, peripheral blood eosinophilia was detected in 17 (56.7%) patients and the degree of eosinophilia was median 1,073/μL (692/μL, 1,661/μL) although 7 of them pretreated with systemic corticosteroids. Of the 26 patients with CSF analyses, only 4 patients (15.4%) showed pleocytosis (≥5/μL), 9 patients (34.6%) showed the presence of eosinophils, and 8 patients (30.8%) showed CSF eosinophilia (≥5%). All 37 patients had hyperIgEaemia and the median level of serum IgE was 937 IU/mL (523 IU/mL, 2,302 IU/mL). Of the 31 *Toxocara* sero-positive patients, all had hyperIgEaemia and the median level of serum IgE was 1,226 IU/mL (534 IU/mL, 3,031 IU/mL).

Parasite and *Toxocara* serologic findings

For the 33 patients who underwent serum TES IgG ELISA, 31 patients (93.9%) had positive values (Mean ± SD of absorbance, 2.02 ± 0.67). Among the 31 *Toxocara*-seropositive patients, all had specific IgE to *D. farinae* and only two of them (6.5%) showed a positive reaction against cysticercus and sparganum antigen, respectively. There was significant correlation between the *Toxocara*-specific IgG values and the serum IgE levels (ρ=0.632, P<0.001). Positive ELISA results for *Toxocara* were confirmed by IgE western blot with a typical pattern of *Toxocara* specific bands in the low molecular weight fractions in 8 of 11 patients (Fig. 1). Of the 10 patients who underwent CSF TES IgG ELISA, all had positive values (Mean ± SD of absorbance, 1.90 ± 0.85).

![IgE binding to TES Antigens on blotting strips. Serum of A, B were obtained from toxocariasis patients with liver abscess. Serum C was obtained from AM patient with Toxocara-IgG positivity. Serum of D, E, and F were obtained from *D. farinae* specific allergic rhinitis patients. Lane A, B, and C revealed a typical pattern of Toxocara specific bands in low molecular weight fractions.](image)

![Radiologic images from 45-yr-old man whose first symptoms were chest tightness and progressive lower extremities weakness. He used to eat uncooked cow liver one or two times a month. The peripheral blood showed leukocytosis (11,090/μL) with 33% eosinophils and hyperIgEaemia (2,724 U/mL). The values of specific IgE to *D. pteronyssinus* and *D. farinae* were 1.4 U/mL and 4.98 U/mL, respectively although he showed negative skin-prick test results to common aeroallergens. The ELISA test for *Toxocara canis* was strongly positive (absorbance 2.195). (A-D) Initial transverse CT scan showing a lung nodule with halo sign and multiple low attenuating nodules in the liver. (E-H) One month follow up transverse CT scan showing migrating nodules in the lung and liver. (I, J) T2-weighted MRI images with high signal intensity lesions at the cervical spinal cord.](image)
Regarding the spinal cord MRI, 2 patients showed normal finding and another 2 patients showed bulging discs. Localized spinal cord lesions were detected in 32 of 36 patients (88.6%) and the thoracic cord (43.8%) was the most frequently observed lesion, followed by the cervical (37.5%), both the cervical and thoracic (15.6%) and the lumbar cord (3.1%) in that order. Thirty-one of 32 patients (96.9%) showed high signal intensity lesions on the T2-weighted images and 78% of them showed involvement of more than 2 segments (range, 1-8; median, 2). Twenty-six patients (81.3%) had spinal cord swelling and 24 patients (75.0%) showed nodular or patchy contrast enhancement (Fig. 2).

Based on image findings of eosinophilic infiltrations in the lung, four of 36 patients (11.1%) had positive results. Among the 4 patients with positive lung findings, two of 36 patients who underwent chest radiography showed evidence on the imaging findings of eosinophilic infiltration while 3 of 4 patients who underwent chest computed tomography (CT) showed positive results. Based on image findings of eosinophilic infiltrations in the liver, 7 of 22 patients (31.8%) had positive results. Among the 7 patients with positive liver findings, 4 of 19 patients who underwent hepatic sonography showed eosinophilic liver abscess findings while 4 of 6 patients who underwent liver CT showed positive results.

### Treatment response

The treatment outcome data are summarized in Table 3. The post-treatment follow up period was $450 \pm 273$ days (Mean $\pm$ SD). Out of 31 *Toxocara* myelitis patients, 20 had additive albendazole treatment. There were no demographic and biological differences between conventional corticosteroid treatment group and additive albendazole treatment group. Analysis of the results showed a significant decrease of the clinical score in both groups after treatment but additional albendazole treatment was more efficient when it was compared as responder and non-responder ($P=0.032$) (Fig. 3).

Moreover, early albendazole treatment subgroup (within 1 yr from symptom development, n=13) had better response in the clinical score ($P=0.015$) than late albendazole treatment subgroup. Serum *Toxocara*-specific IgG levels were decreased in both group (each, $P=0.001$, $P=0.042$) while serum total IgE levels were significantly decreased only in the additional albendazole treatment group (each, $P=0.013$, $P=0.139$). But, serum ECP levels were not significantly decreased after treatment in both groups.

Improvement of spinal MRI findings (resolution or decrease of high signal intensities on T2WI were observed in 1 of 3 conventional corticosteroid group and 3 of 5 additional albendazole treatment group.

### DISCUSSION

*AM* is one of the idiopathic transverse myelitis associated with atopic disease or diathesis. The stepwise progression and fluctuation of the symptoms are frequent in *AM* but the pathomechanism is still unknown (1). *Toxocarasis* is one of the most prevalent parasitic infections in the world, caused by larval stage of *Toxocara* spp. It is usually non-fatal disease, but the larvae can migrate through the CNS system and may

---

**Table 3. Summary of treatment response from 31 patients with *Toxocara* myelitis**

|                      | Before treatment | After treatment | $P$   |
|----------------------|------------------|----------------|------|
| **Clinical score**   |                  |                |      |
| Conventional         | 5                | 3              | 0.009|
| Albendazole          | 5                | 3              | <0.001|
| **Total IgE (U/mL)** |                  |                |      |
| Conventional         | 1,346            | 1,280          | 0.139|
| Albendazole          | 1,017            | 619            | 0.013|
| **ECP (ng/mL)**      |                  |                |      |
| Conventional         | 56               | 15             | 0.611|
| Albendazole          | 22               | 6.9            | 0.285|
| **Toxocara ELISA titer (absorbance)** |      |                |      |
| Conventional         | 3.23             | 2.25           | 0.042|
| Albendazole          | 2.86             | 2.13           | 0.001|

ECP, eosinophilic cationic protein; ELISA, enzyme-linked immunosorbent assay.
cause such neurologic manifestations in AM. The frequency and localization of *Toxocara* larvae in the spinal cord in humans are unknown. Following a high dose and repeated infections by *T. canis*, some larvae can migrate to the spinal cord and induce local inflammation with immediate-type and delayed-type hypersensitivity, along with clinical symptoms. Accurate diagnosis of toxocariasis is not possible sometimes, because the diagnostic method is not available worldwide although increased awareness of this disease. We could infer that many patients who were diagnosed as having AM might have *Toxocara* myelitis.

Our clinical and MRI imaging findings were similar with those of previously reported in AM except for the difference in the male preponderance (1). Many Koreans, and especially the males, have a custom of eating raw animal tissue in their social life based on the belief that is health-promoting food, and so the chances of being infected by *Toxocara* larvae might be more likely increased in Korean males (6).

The data presented herein suggested that the *Toxocara*-sero-prevalence in AM patients was approximately 94% and the neuropathological mechanism of AM might be due to neural involvement by *Toxocara* larvae if one takes into account: 1) the positive histories of ingesting raw liver/meat, which is known to be the main risk factor for toxocariasis in adults (6), 2) the accompanied eosinophilic infiltration in the lung and liver (27), 3) the positive serology in both sera and CSF with IgG anti-*Toxocara*, and some of the patients had this confirmed by IgE western blotting using TES antigen, 4) the relatively higher *Toxocara* ELISA values (absorbance > 1.5) that are associated with active or recent clinical toxocariasis (9, 10), 5) the peripheral blood eosinophilia and an increase in the concentration of serum total IgE, (>500 IU/mL), which are further evidence of recent *Toxocara* infection (12), 6) the improvement of signs and symptoms after treatment with albendazole in several cases in our preliminary study and better treatment responses after early additional albendazole treatment in sub-group analysis.

A diagnosis of toxocariasis is made by detection of antibody by using ELISA because the histological proof of *Toxocara* larvae in tissue is extremely difficult and there is little serologic cross-reaction between toxocariasis and other helminthiases (12). The diagnostic sensitivity is superior to 90% and specificity of the reaction is also high. However, an ELISA kit for this disease is not widely available and it is not capable of distinguishing between current and past infection. So when interpreting a serologic result and selecting candidates for anthelminitics therapy, we feel that the immunologic test should be accompanied by full history taking and laboratory tests. Therefore, the food habits of suspected patients should be assessed and *Toxocara* myelitis should be suspected in those AM patients with a positive history of raw animal tissue ingestion. Moreover, all our patients had hyperIgEaemia, about 60% of them had peripheral blood eosinophilia, and about 30% of them had eosinophilic liver abscess (27), and these findings might give us additional help to diagnose toxocariasis, although long-standing toxocariasis with no or minor systemic involvement except CNS infection might explain the lack of a specific immune response in blood or other organs.

In our study, out of total 11 patients with positive ELISA results for *Toxocara*, only 8 patients were confirmed by IgE western blot with a typical pattern of *Toxocara* specific bands in the low molecular weight antigen of 24, 28, 30, and 35 kDa. This discrepancy could have been due either to cross-reactivity due to helminthic disease other than toxocariasis or to some patients’ selective protein antigen components destroyed during the boiling process. The value of additional Western blotting for corroborating serological results cannot be overstated, but it might be more helpful in cases in which the TES-ELISA values lie under the cut-off or to rule out cross-reactivity due to other helminthic diseases as magnaval et al. suggested in their study (28).

Further investigations needed to determine the association of *Toxocara* specific antibody and mite specific antibody. One possible explanation is that the false positivity of mite specific antibody due to increased production of the serum total IgE. This is supported by 1) the negative skin prick test results in the available 8 AM patients with atopic diathesis who showed *Toxocara* sero-positivity, 2) the relatively low serum value of specific IgE to *D. farinae*, in 87% of the 23 atopic diathesis patients, less than 10 IU/mL. Allergenic cross-reactivity between the nematode *T. canis* and the dust mite *D. farinae* might also be a possible explanation. Several studies have suggested there is allergenic cross-reactivity between *Anisakis* *simplex* and other nematode (29). Allergenic cross-reactivity between *A. simplex* and four different dust-mite species has also been reported (30). Therefore, we investigated a possible allergenic cross-reactivity between *T. canis* and *D. farinae*. We performed western blotting using TES antigens and whole body extracts of *D. farinae* in some selected patients with both atopic diathesis and *Toxocara* sero-positivity. In case of western blotting using whole body extracts of *D. farinae*, none of 6 patients showed a typical pattern of *D. farinae* specific bands as shown in positive controls with mite-specific allergic rhinitis. In *Toxocara*-ELISA inhibition tests using extracts of *D. farinae* varying from 1, 10, 100, to 1,000 μg/mL of concentration, no inhibition was observed in any of the 2 selected sera. So we concluded that mite-antigen specific IgE positivity in AM patients with *Toxocara* sero-positivity is false positive results with increased production of total IgE, rather than allergenic cross-reactivity between whole body extracts of *D. farinae* and TES antigens although the results are not shown here.

In summary, our study reveals that there is a high prevalence of toxocariasis in patients with atopic myelitis. Taking a good history and performing *Toxocara* ELISA should be done for evaluating the causes of atopic myelitis. Liver or lung nodules seen on imaging studies can support diagnosis of *Toxocara* myelitis.
REFERENCES

1. Osoegawa M, Ochi H, Minohara M, Murai H, Umehara F, Furuya H, Yamada T, Kira J. Myelitis with atopic diathesis: a nationwide survey of 79 cases in Japan. J Neurol Sci 2003; 209: 5-11.

2. Kira J, Yamasaki K, Kawano Y, Kobayashi T. A case-control study. Parasitology 1997; 115: 537-43.

3. Kira J, Horiuchi I, Suzuki J, Osoegawa M, Tobimatsu S, Murai H. Human toxocariasis. Epidemiol Rev 1981; 3: 230-50.

4. Osoegawa M, Ochi H, Kikuchi H, Shirabe S, Nagashima T, Tsumoto T, Tamura Y, Yamabe K, Takahashi H, Iwaki T, Kira J. Eosinophilic myelitis associated with atopic diathesis: a combined neuroimaging and histopathological study. Acta Neuropathol 2003; 105: 289-95.

5. Kira J. Atopy and neural damage. Intern Med 2002; 41: 169-74.

6. Kwon NH, Oh MJ, Lee SP, Lee BJ, Choi DC. The prevalence and diagnostic value of toxocariasis in unknown eosinophilia. Ann Hema tol 2006; 85: 233-8.

7. Magnaval JF, Galindo V, Glickman LT, Clanet M. Highlights of human toxocariasis. Korean J Parasitol 2001; 39: 1-11.

8. Glickman LT, Schantz PM. Toxocariasis: serological diagnosis by enzyme immunoassay. J Clin Pathol 1979; 32: 284-8.

9. de Savigny DH, Voller A, Woodruff AW. Toxocariasis: serological diagnosis by enzyme immunoassay. J Clin Pathol 1979; 32: 284-8.

10. Moreira-Silva SF, Rodrigues MG, Pimenta JL, Gomes CP, Freire-Martins S, Veloso E, De Souza M, Velludo R, Leite J, Carneiro Neto G, Pereira E. The prevalence and diagnostic value of toxocariasis in unknown eosinophilia. Ann Hema tol 2006; 85: 233-8.

11. Wang C, Huang CY, Chan PH, Preston P, Chau PY. Transverse myelitis associated with larva migrans: finding of larva in cerebrospinal fluid. Lancet 1983; 1: 423.

12. Park HY, Lee SU, Huh S, Kong Y, Magnaval JF. A seroepidemiological survey for toxocariasis in apparently healthy residents in Gangwon-do, Korea. Korean J Parasitol 2002; 40: 113-7.

13. Magnaval JF, Galindo V, Glickman LT, Clanet M. Human toxocara infection of the central nervous system and neurological disorders: a case-control study. Ann Neurol 1997; 115: 537-43.

14. Strupp M, Pfister HW, Eichenlaub S, Arbusow V. Meningomyelitis in a case of toxocariasis with markedly isolated CSF eosinophilia and an MRI-documented thoracic cord lesion. J Neurol 1999; 246: 741-4.

15. Eberhardt O, Bialek R, Nagle T, Dichgans J. Eosinophilic meningomyelitis in toxocariasis: case report and review of the literature. Clin Neurol Neurosurg 2005; 107: 432-8.

16. Kumar J, Kinm J. MR in Toxocara canis myelopathy. AJNR Am J Neuroradiol 1994; 15: 1918-20.

17. Russeger L, Schmutzhard E. Spinal toxocara abscess. Lancet 1989; 2: 398.

18. Engel H, Spieckermann DA, Tismer R, Mohbi W. Acute meningomyelitis due to Toxocara larvae. Dtsch Med Wochenschr 1971; 96: 1498.

19. Muller-Jensen A, Schall J, Weisner B, Lamina J. Eosinophilic meningoencephalomyelitis and visceral syndrome caused by Ascaris lumbricoides larvae in adults. Dtsch Med Wochenschr 1973; 98: 1175-7.

20. Sellal F, Picard M, Marescaux C, Collard M, Magnaval JF. Myelitis caused by Toxocara canis (larva migrans). Rev Neurol (Paris) 1992; 148: 53-5.

21. Ota S, Komiyama A, Jokura K, Hasegawa O, Kondo K. Eosinophilic meningoencephalomyelitis due to Toxocara canis. Rinsho Shinkeigaku 1994; 34: 1148-52.

22. Duprez TP, Bigaignon G, Delgrange E, Desfontaines P, Hermans M, Vervoort T, Sindic CJ, Buysschaert M. MRI of cervical cord lesions and their resolution in Toxocara canis myelopathy. Neuroradiology 1996; 38: 792-5.

23. Goiffet S, Jeanjean AP, Duprez TP, Bigaignon G, Sindic CJ. Eosinophilic pleocytosis and myelitis related to Toxocara canis infection. Eur J Neurol 2000; 7: 703-6.

24. Osoegawa M. Diagnosis and treatment of CNS parasite infection with special reference to parasitic myelitis. Rinsho Shinkeigaku 2004; 44: 961-4.

25. Dauriac-Le Masson V, Chochon F, Demeret S, Pierrot-Deseilligny C. Toxocara canis meningoencephalomyelitis. J Neurol 2005; 252: 1267-8.

26. Moreira-Silva SF, Rodrigues MG, Pimenta JL, Gomes CP, Freire LH, Pereira FE. Toxocariasis of the central nervous system: with report of two cases. Rev Soc Bras Med Trop 2004; 37: 169-74.

27. Chang S, Lim JH, Choi D, Park CK, Kwot NH, Cho SY, Choi DC. Hepatic visceral larval migrans of Toxocara canis: CT and sonographic findings. AJR Am J Roentgenol 2006; 187: W622-9.

28. Magnaval JF, Fabre R, Maurieres P, Charlet JP, de Larrard B. Myelitis caused by Toxocara canis (larva migrans). Rev Neurol (Paris) 1996; 148: 199-203.

29. Kennedy MW, Tierney J, Ye P, McMonagle FA, McIntosh A, McLaughlin D, Smith JW. The secreted and somatic antigens of the third stage larva of Anisakis simplex, and antigenic relationship with Ascaris lumbricoides, and Dermatophagoides pteronyssinus. Allergy 2001; 56: 660-6.